SCHEDULE: Morgan Stanley Discloses 6% Stake in PROKIDNEY CORP.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a 6.0% beneficial ownership stake in PROKIDNEY CORP.'s Class A Common Stock as of December 31, 2025.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., collectively beneficially own 8,519,982 shares of PROKIDNEY CORP. Class A Common Stock.
• This ownership represents 6.0% of the total Class A Common Stock outstanding.
• The filing date for this Schedule 13G was February 12, 2026, reflecting the ownership position as of December 31, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of PROKIDNEY CORP.
• Morgan Stanley Investment Management Inc. is a wholly-owned subsidiary of Morgan Stanley, and its holdings are included in Morgan Stanley's reported beneficial ownership.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable institution like Morgan Stanley can instill investor confidence, although the filing itself is routine.

Positives

• Significant institutional investment from a major financial institution like Morgan Stanley can signal confidence in PROKIDNEY CORP.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a passive investment strategy, reducing concerns about potential activist interventions.

Future Outlook

NA

Management Comments

• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, often indicating a long-term investment perspective from major financial players. For a biotechnology or pharmaceutical company like PROKIDNEY, a substantial institutional holding can be viewed positively by the market, suggesting validation of its pipeline or market potential.

Stakeholder Impact

• Shareholders: May view the significant institutional ownership as a positive signal, potentially increasing confidence in the stock.
• Management: Could see this as a vote of confidence from a major financial institution.

Key Dates

Recommendation

The disclosure of a significant 6% stake by Morgan Stanley indicates institutional confidence in PROKIDNEY CORP. While this filing does not provide new operational or financial data, the presence of a major institutional investor typically offers a degree of stability and validation, suggesting a 'hold' for existing investors and a signal for potential new investors to conduct further due diligence.

Keywords

PROKIDNEY CORP, Morgan Stanley, Morgan Stanley Investment Management, Class A Common Stock, Beneficial Ownership, Schedule 13G, Institutional Investor, Equity Stake, 74291D104